Ferroptosis as a vulnerability in cancer

a. Therapy-resistant cancer cells with specific cellular states are vulnerable to ferroptosis, for example cancer cells with a mesenchymal phenotype that are enriched in polyunsaturated fatty acids (PUFAs) owing to high expression of zinc finger E-box binding homeobox 1 (ZEB1), elongation of very long-chain fatty acid protein 5 (ELOVL5) or fatty acid desaturase 1 (FADS1). Similarly, dedifferentiated subtypes of melanoma cells are characterized by PUFA accumulation and a deficiency of reduced glutathione (GSH), which render these cells vulnerable to ferroptosis. In addition, certain cancer cells, such as clear-cell renal cell carcinoma (ccRCC), non-neuroendocrine (NE) small-cell lung cancer (SCLC), and triple-negative breast cancer (TNBC) cells are inherently susceptible to ferroptosis owing to their unique metabolic features, such as high levels of PUFA-containing ether phospholipids (ePLs).b. Mutations in certain tumour suppressors or oncogenes render cancers vulnerable to ferroptosis. Inactivating mutations in any constituent of the tumour-suppressive E-cadherin– neurofibromin 2 (NF2)–Hippo pathway confers a vulnerability to ferroptosis by upregulating Yes-associated protein (YAP)- or transcriptional coactivator with PDZ-binding motif (TAZ)-mediated transcription of ferroptosis-promoting factors, such as acyl-coenzyme A synthetase long chain family member 4 (ACSL4), transferrin receptor 1 (TfR1) and NADPH oxidase 4 (NOX4). In ccRCC, mutation or loss of Von Hippel-Lindau (VHL) promotes hypoxia inducible factor (HIF)-dependent expression of hypoxia-inducible, lipid droplet-associated protein (HILPDA), rendering ccRCCs vulnerable to ferroptosis. Non-small-cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) mutations are vulnerable to ferroptosis because of their high dependence on cystine. In another example, isocitrate dehydrogenase 1 (IDH1)-mutated cancer cells with increased levels of the oncometabolite 2-hydroxyglutarate (2-HG) are sensitive to ferroptosis owing to their decreased glutathione peroxidase 4 (GPX4) levels. * indicates either a mutation or loss of the gene, dependent on the gene.c. Vulnerability to ferroptosis is triggered by an imbalance between GPX4-dependent and GPX4-independent ferroptosis defence systems. Cancer cells with low expression of components of GPX4-independent systems (such as ferroptosis suppressor protein-1 (FSP1), dihydroorotate dehydrogenase (DHODH) or GTP cyclohydroxylase-1 (GCH1)) depend on GPX4 for survival and therefore are vulnerable to GPX4 inhibition. Conversely, cancer cells with low expression of GPX4 are sensitive to inactivation of components of GPX4-independent systems. The dashed lines indicate that the function of the indicated protein is diminished or blocked in the corresponding context. PLs, phospholipids.
Ferroptosis as a vulnerability in cancer

Publication

Targeting ferroptosis as a vulnerability in cancer. (2023) Guang Lei, et al. Nat Rev Cancer. ;22(7):381-396. Figure: F2.

Gene mentions


Organism Group Word Match Source NCBI Symbol NCBI ID
Homo sapiens Primates GPX4 GPX4 ncbigene_symbol GPX4 2879
Homo sapiens Primates ELOVL5 ELOVL5 ncbigene_symbol ELOVL5 60481
Homo sapiens Primates DHODH DHODH ncbigene_symbol DHODH 1723
Homo sapiens Primates FSP1 FSP1 ncbigene_synonym S100A4 6275
Homo sapiens Primates FSP1 FSP1 ncbigene_synonym ATL1 51062
Homo sapiens Primates FSP1 FSP1 ncbigene_synonym AIFM2 84883
Homo sapiens Primates GCH-1 GCH1 ncbigene_symbol GCH1 2643
Homo sapiens Primates SCLC SCLC ncbigene_synonym SCLC1 7864
Homo sapiens Primates E-cadherin CDH1 ncbigene_symbol CDH1 999
Homo sapiens Primates E-cadherin CDH1 ncbigene_synonym FZR1 51343
Homo sapiens Primates EGFR* EGFR ncbigene_symbol EGFR 1956
Homo sapiens Primates NF2 NF2 ncbigene_symbol NF2 4771
Homo sapiens Primates VHL VHL ncbigene_symbol VHL 7428
Homo sapiens Primates IDH1* IDH1 ncbigene_symbol IDH1 3417
Homo sapiens Primates YAP YAP ncbigene_synonym YAP1 10413
Homo sapiens Primates TFRC TFRC ncbigene_symbol TFRC 7037
Homo sapiens Primates ACSL4 ACSL4 ncbigene_symbol ACSL4 2182
Homo sapiens Primates NOX4 NOX4 ncbigene_symbol NOX4 50507
Homo sapiens Primates HILPDA HILPDA ncbigene_symbol HILPDA 29923

Chemical mentions

Word Match MeSH Name ChEBI
iron Iron mesh:D007501 iron atom chebi:18248
GPX4-GSH Glutathione mesh:D005978 glutathione chebi:16856
PUFA Fatty Acids, Omega-3 mesh:D015525 omega-3 fatty acid chebi:25681
cystine Cystine mesh:D003553 cystine chebi:17376

Disease mentions

Word Match MeSH Name DOID
cancer NA mesh:D009369
VHL NA mesh:D006623